title: [Progress on clinical application of bevacizumab for the treatment of refractory cervical cancer].
abstract: Bevacizumab is increasingly used in recurrent, persistent or metastatic cervical cancer. The early retrospective case reports found that bevacizumab combined with 5-FU (including capecitabine) or paclitaxel was well tolerated and displayed encouraging anti-tumor activity in recurrent or persistent cervical cancer. Phase Ⅱ clinical trials showed that bevacizumab was well tolerated and active in the second- and third-line treatment of patients with recurrent cervical cancer. Large scale phase Ⅱ and phase Ⅲ clinical trials demonstrated that bevacizumab-containing chemotherapy was effective in the first- and second-line treatment of patients with persistent cervical cancer, prolonged survival time and improved remission rate. The article also reviews the research progress on predictive factors of bevacizumab efficacy, showing the use of imaging and biomarkers in predicting the efficacy of bevacizumab treatment. In addition, this article analyzes the cost-effectiveness of bevacizumab, finding that bevacizumab combined with chemotherapy meets the standard of cost-effectiveness.
authors.affiliation: Department of Radiation Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710000, China.
authors.forename: Bin
authors.initials: B
authors.lastname: He
authors.affiliation: Department of Radiation Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710000, China.
authors.forename: Yanlan
authors.initials: Y
authors.lastname: Chai
authors.affiliation: Department of Radiation Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710000, China.
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
authors.affiliation: Shanghai Roche Pharmaceutucals Ltd., Shanghai 201203, China. zhenxing.zhou@roche.com.
authors.forename: Zhenxing
authors.initials: Z
authors.lastname: Zhou
authors.affiliation: Department of Radiation Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710000, China. liuzmail@163.com.
authors.forename: Zi
authors.initials: Z
authors.lastname: Liu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005260:Female; D005472:Fluorouracil / Q000191:economics / Q000627:therapeutic use; D017048:Health Care Costs; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017239:Paclitaxel / Q000191:economics / Q000627:therapeutic use; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000401:mortality
chemical_list: D000068258:Bevacizumab; D017239:Paclitaxel; D005472:Fluorouracil